In this study, we have localized an enhancer element in the 5'-¯anking region of the HGF gene promoter and have identi®ed its functional transcriptional factors. Through transient transfection of NIH3T3 ®broblast cells and gel mobility shift assays, the functional binding site was localized to a short region (7318 to 7303 bp from the transcription start site) which has a CTCCC sequence. This motif is also conserved in the human HGF promoter and acts as a binding site for the Sp family of transcription factors. In the presence of NIH3T3 nuclear protein extracts, this enhancer region formed speci®c DNA-protein complexes which were totally abrogated by excess amounts of consensus Sp1 oligonucleotide. In gel mobility supershift assays, antiSp1 and anti-Sp3 antibodies speci®cally recognized these complexes as was evident by their slower migration. Sitespeci®c mutation of this binding motif resulted in total loss of Sp1 and Sp3 binding and a concomitant loss of enhancer function within the context of the HGF promoter. Furthermore, in transient cotransfection assays, overexpression of Sp1 and/or Sp3 stimulated HGF promoter activity independently and additively through binding to the Sp1 binding site in the HGF gene promoter region. DNaseI hypersensitive analysis of freshly isolated nuclei from NIH3T3 cells revealed that ®ve hypersensitive sites (HSS) are present within the 2 kb region immediately upstream of the HGF promoter. One of these sites was mapped to position 70.3 kb from the transcription start site. These data show that both Sp1 and Sp3 transcription factors upregulate HGF promoter activity by binding to the Sp1 binding site at position 7318 to 7303 bp in the HGF gene promoter.
Introduction
Hepatocyte growth factor (HGF) 1 , originally identi®ed as the main mitogenic component of serum and platelets for normal adult rat hepatocytes (Zarnegar and Michalopoulos, 1989; Nakamura et al., 1989) and other cell types , is a multifunctional cytokine that induces growth and morphogenesis (For review, see Rubin et al., 1993; Rosen et al., 1994; Zarnegar and Michalopoulos, 1995; Matsumoto and Nakamura, 1996) . HGF aects a variety of cell types, especially those of epithelial origin, via binding and activating its speci®c cell surface receptor known as Met ; also see Matsumoto and Nakamura, 1996) . HGF elicits responses in its target cells such as mitogenesis (Stoker et al., 1991; Bussolino et al., 1992) , morphogenesis (Montesano et al., 1991; Uehara et al., 1992) , motogenesis and metastogenesis (Stoker et al., 1987; Gherardi et al., 1989; Rosen et al., 1990; Weidner et al., 1990) . In vivo studies in which HGF was implanted into rabbits demonstrated that HGF also has angiogenic activity (Bussolino et al., 1992) . This growth factor plays an important role in the regeneration of various organs such as liver, lung and kidney (Lindroos et al., 1991; Matsumoto et al., 1991; Kono et al., 1992) . Localization of HGF in the developing mammalian embryo in a tissue-speci®c, time-dependent way suggests that HGF expression is developmentally regulated (DeFrances et al., 1992; Sonnenberg et al., 1993) and that inappropriate HGF expression may be detrimental to growth and development. Lack of HGF, as shown by gene knock-out studies in mice, results in improper ontogeny of several organs including the placenta, liver and muscle leading to inutero/utero demise (Schmidt et al., 1995; Uehara et al., 1995) . Overexpression of HGF in transgenic mice, on the other hand, is accompanied by an abnormal migration and dierentiation of skeletal muscle and neural crest progenitor cells during embryonic development (Takayama et al., 1996) . These ®ndings highlight that proper expression of HGF is essential for normal tissue growth and dierentiation.
Studies indicate that peptide growth factors play an important role in the development and progression of cancer (For review, see Aaronson, 1991) . Experimental and clinical investigations of HGF have revealed that aberrant HGF/Met signaling contribute to the tumorigenesis of various neoplasms such as sarcomas (Rong et al., 1993; Maier et al., 1996) , carcinomas (Ebert et al., 1994) , gliomas (Rosen et al., 1996) and leukemias (Hino et al., 1996) . For example, coexpression of human Met and HGF caused normal cell lines such as NIH3T3 ®broblasts and C127 cells to become tumorigenic in nude mice and acquire an invasive and metastatic phenotype (Tsarfaty et al., 1994; Rong et al., 1994; Jeers et al., 1996) . HGF gene expression is tightly regulated at the transcriptional level and is restricted to mesenchymallyderived cells such as ®broblasts, macrophages, peripheral blood leukocytes and endothelial cells. HGF mRNA expression is modulated by some cytokines and hormones (Rubin et al., 1993; Zarnegar and Michalopoulos, 1995) , and its gene expression is disregulated in human neoplasms. Therefore, elucida-tion of the mechanisms controlling HGF expression at the transcriptional level is critical for understanding the molecular basis of HGF's expression and function in physiological and pathological conditions. To understand the transcriptional regulation of the HGF gene, its promoter region has been cloned and partially characterized by several groups (Miyazawa et al., 1991; Okajima et al., 1993; Liu et al., 1994; Aravamudan et al., 1993; Plaschke-Schlutter et al., 1995; Jiang et al., 1997) . Previous independent work on the characterization of the mouse HGF promoter from our laboratory (Liu et al., 1994) and others (Plaschke-Schlutter et al., 1995) showed that within 200 bp (70.5 to 70.3 kb) of the 5'-¯anking region of the mouse HGF promoter, a strong positive-acting element(s) exists.
In the present work, we have further characterized this enhancer element and its cognate transcription factors. By using transient transfection and gel mobility band shift assays, the enhancer element was mapped to a potential Sp1 binding region (7318 to 7303 bp from the transcription start site) which has a CTCCC motif and is highly conserved in rodent and human HGF promoters. Gel mobility supershift assays revealed that nuclear proteins that interact with this sequence are Sp1 and Sp3 transcription factors. After the Sp1 binding site was mutated, the enhancing function of this region was diminished. In cotransfection experiments, high expression of both Sp1 and/or Sp3 dramatically stimulated HGF promoter activity. DNaseI hypersensitive analysis of freshly isolated nuclei from NIH3T3 cells revealed that ®ve hypersensitive sites (HSS) are present within the 2 kb immediately upstream of the HGF promoter. Interestingly, one of these sites mapped to position 70.3 kb from the transcription start site. These data reveal that Sp1 and Sp3 stimulate the HGF promoter by binding to the Sp1 site in the HGF gene promoter.
Results

Identi®cation of an enhancer in the mouse HGF promoter
Previous independent work on the characterization of the mouse HGF promoter from our laboratory (Liu et al., 1994) and others (Plaschke-Schlutter et al., 1995) showed that within 200 bp (70.5 to 70.3 kb) of the 5'-¯anking region of the mouse HGF promoter, a strong positive-acting element(s) resides. To further de®ne and characterize the positive acting element(s) and its cognate factor(s), additional HGF promoter constructs, namely 0.4 HGF-CAT and 0.4 DHGF-CAT, were generated. We used four HGF-CAT constructs including 0.3, 0.4, 0.4 D and 0.5 HGF-CAT to perform CAT assays for determination of HGF promoter activity in NIH3T3 ®broblasts. As shown in Figure 1a , 0.5 HGF-CAT and 0.4 HGF-CAT constructs had signi®cantly higher CAT activity than did the 0.4 DHGF-CAT and 0.3 HGF-CAT constructs. This result suggests that the region between 70.3 and 70.4 kb contains a positive element(s) which upregulates HGF promoter activity. This ®nding is in agreement with that of Plaschke-Schlutter et al. (1995) who also showed that a strong positive regulatory region exists in the mouse HGF promoter between 7365 and 7291 bp from the transcription start site. To examine whether any trans-acting factors specifically bound to this region, we performed gel mobility shift assays using an end-labeled 111 bp DNA fragment (from 7384 to 7274 bp) and NIH3T3 cell nuclear protein extract. Two speci®c DNA-protein complexes (t, top complex; b, bottom complex) were detected ( Figure 1b; lanes 2 and 3) . Addition of increasing amounts of unlabeled DNA probe to the binding reaction resulted in dose dependent competition for binding (Figure 1b ; lanes 4 ± 7). Unrelated DNA fragments did not compete (see Figures 2 and 3 ). These experiments demonstrate that the positive regulatory region binds speci®cally to nuclear protein(s), and these proteins may be responsible for the enhancing function of this region.
Sequence of the binding region
To identify the binding region, ®ve dierent oligonucleotides encompassing the entire 111 bp fragment were synthesized and used as competitors in gel mobility shift assays (Figure 2a) . The oligonucleotides P1, P2 and P3 together cover the whole 111 bp region (from 7384 to 7274 bp), while oligonucleotide P4 overlaps P1 and P2 fragments and oligonucleotide P5 overlaps P2 and P3 fragments (Figure 2a ). Only oligonucleotide P5 abolished complex formation (Figure 2a, lane 7) . The result suggests that P5 (7328 to 7297 bp) contains the binding region for the nuclear protein factor(s). To further narrow down this binding sequence and de®ne its binding motif, six dierent shorter versions of P5 oligonucleotide, namely P5-I, P5-II, P5-III, P5-IV, P5-V and P5-VI, were synthesized and used as competitors in gel mobility shift assays ( Figure 2b ). All of the shorter forms of P5 oligonucleotide (P5-I to P5-V) except P5-VI totally competed for binding to the labeled probe (Figure 2b ; lanes 3 ± 8). Based on these results, we conclude that the binding region is within the ®fteen nucleotides 7318 to 7303 bp of the mouse HGF promoter.
Identi®cation of the binding factors as Sp1 and Sp3 of the Sp family of transcription factors
Computer analysis of this binding region revealed that it harbors a potential Sp1 binding site having a CTCCC motif. When we used consensus Sp1 oligonucleotide as a competitor in gel mobility shift assays, it totally competed with the two complexes (t and b) formed by P5 (Figure 3a ; lane 5). Mutant forms of Sp1 oligonucleotide, on the other hand, did not show any competitive eects (Figure 3a ; lane 6). Other unrelated oligonucleotides including Ap1, Ap2, SRE, Stat3, CRE, NF-kb and Egr-1 sequences were also used as competitors and did not compete (data not shown). According to these data, we synthesized a mutant form of P5 in which the Sp1 binding site was mutated (CC was changed to AA) and used it as a competitor ( Figure 3a) . It was found that P5 binding activity for these transcriptional factors was totally abolished after this mutation (Figure 3a ; lane 4). Based on these results, we hypothesized that these complexes may be members of the Sp family of transcription factors. To test our hypothesis, supershift assays were carried out using anti-Sp1 and anti-Sp3 antibodies. We found that the top complex is composed of Sp1 and Sp3, and the bottom complex mainly consists of Sp3 (Figure 3b ; lanes 2 ± 9). As expected, the negative control anti-AP2 and anti-ER antibodies did not have any eect (Figure 3b; lanes 10, 11 and 12) . These results clearly demonstrate that Sp1 and Sp3 bind to the enhancer region and form these protein-DNA complexes. Because the P5 region of the human (from 7347 to 7316 bp) and mouse HGF gene promoters are very conserved (Figure 4a ), we carried out cross competition gel mobility shift assays and super shift assays using human P5 or mouse P5 as a competitor or as a probe, respectively. We found that human P5 fragment also eectively binds to the Sp1 and Sp3 transcription factors ( Figure 4 ). These results strongly suggest that the Sp1 and Sp3 binding site in the human HGF gene promoter has the same regulatory functions as that in the mouse HGF gene promoter. To test whether Sp1 and/or Sp3 aect HGF gene promoter activity, three HGF-CAT constructs harboring a CC to AA mutation in their Sp1 binding site in the P5 region were generated. These mutant constructs and their wild type counterparts (1.4 HGF-CAT, 0.7 HGF-CAT and 0.4 HGF-CAT (Figure 5)) were used to determine promoter activity by transiently transfecting these constructs into NIH3T3 cells and performing CAT assays. As shown in Figure 5 , the activity of the HGF promoter constructs harboring the Sp1 site mutation are drastically reduced to approximately 25% of that of the wild type promoter. These results ®rmly demonstrate that the Sp1 binding site in the HGF gene promoter region has a positive regulatory function on this gene and that Sp1 and Sp3 may be involved in this process.
It is known that the major regulatory function of Sp1 is upregulation of its target genes. In contrast, the major function of Sp3 is down regulation (although exceptions exist; for example, the PDGF-B promoter was reported to be upregulated by Sp3 (Hagen et al., 1994; Liang et al., 1996) , presumably by competing with Sp1 for the same binding site). Because Sp1 and Sp3 bind to the same DNA sequence, it is dicult to dierentiate their functions by changing the binding site. In the case of the HGF gene, it is possible that Sp3 may also stimulate HGF gene promoter activity through binding to the Sp1 binding site because, as shown in Figures 3 and 4 , Sp3 is the major component of the complexes formed by the Sp1 site of the HGF promoter. To test this hypothesis and directly show that Sp1 and Sp3 are involved in the regulation of the HGF promoter, we performed cotransfection assays using various HGF-CAT constructs and Sp1 and Sp3 expression vectors (2.7 HGF-CAT, 1.4 HGF-CAT, 0.7 HGF-CAT, 0.4 HGF-CAT and 0.1 HGF-CAT constructs with Sp1 and/or Sp3 expression vectors pSV-Sp1 and CMV-Sp3). We made two observations. The ®rst was that the promoter activities of all P and incubated with nuclear protein extract from NIH3T3 cells. Five dierent double-stranded synthetic oligonucleotides (from P1 to P5) which cover dierent regions of the 111 bp DNA fragment were added into the reaction mixture to compete for binding as indicated. Lane 1 was free probe. (b) P5 was labeled and used as a probe. Six dierent short oligonucleotides (P5-I to P5-VI) were used as competitors to further narrow down the binding sequence of these complexes. t and b denote top and bottom speci®c complexes; F is free 32 P-labeled DNA probe. The unlabeled oligonucleotides used as competitors were added to the binding reaction in 100-fold molar excess as compared to that of the labeled probe constructs, except the 0.1 HGF-CAT construct, were dramatically stimulated by Sp1 and/or Sp3 (Figure 6b ). These data clearly reveal that Sp1 and/or Sp3 upregulate HGF promoter activity independently and additively. The second observation was that the strongest response to Sp1 and Sp3 was observed for the 2.7 HGF-CAT construct (13-fold for the 2.7 HGF-CAT, tenfold for the 1.4 HGF-CAT, and sevenfold for the 0.7 and 0.4 HGF-CAT, respectively) ( Figure 6b ). Computer analysis of the 2.7 kb 5'-¯anking region of the HGF gene promoter revealed that ®ve other potential Sp1 binding sites were scattered throughout this region (at positions 71826, 71508, 71319, 71022, and 7202 bp). We have called these Sp1 binding sites`minor Sp1 binding sites' (Figure 6a ) based on the fact that their contribution to HGF promoter activity is low. We draw this conclusion based on the fact that analysis of various 5'-deleted HGF-CAT constructs (2.7 to 0.5 kb transiently transfected into NIH3T3 cells) in which these sites were progressively deleted showed no abrupt changes in promoter activity (Liu et al., 1994; PlaschkeSchlutter et al., 1995) . On the other hand, the major Sp1 site is essential for the activity of the HGF promoter since its deletion/mutation results in a dramatic reduction of HGF promoter activity ( Figure   5 ). It is possible, however, that the minor Sp1 binding sites in the 5'-¯anking region of the HGF promoter cooperate with each other and with the major Sp1 element, therefore showing synergistic stimulation of the HGF gene promoter. Indeed, cotransfection of the Sp1 expression vector with the 1.4 HGF-CAT construct in which the major Sp1 site is mutated resulted in only threefold induction (vs tenfold induction in the corresponding wild type HGF-CAT construct) of HGF promoter activity (data not shown). Of course, we can not exclude the possibility that the major Sp1 binding site may also cooperate with other non-Sp1 transcription factor binding sites in the 2.7 kb 5'-¯anking region of the HGF gene thus resulting in the induction of this gene.
DNaseI hypersensitive sites within the 5'-¯anking region of the mouse HGF promoter
To examine the status of the HGF promoter in the context of its native chromatin structure in vivo, we performed DNaseI hypersensitivity assays. This test reveals regions of chromatin that are accessible to transcription factor binding and that potentially contribute to gene regulation. Freshly prepared nuclei from NIH3T3 ®broblast cells were treated with limited Supershift assays were done as described but oligos corresponding to the human P5 were used as the probes, and the nuclear extract was from human ®broblast MRC-5 cells amounts of DNaseI for a short period of time (one minute on ice). Then, genomic DNA was extracted and digested with the restriction enzymes EcoRI/ HindIII to release a 3.5 kb fragment of the mouse HGF promoter containing 2.8 kb of the 5'-¯anking region, the ®rst exon (90 bp) and part of the ®rst intron (*600 bp) (Liu et al., 1994 ). The digested DNA was then analysed by Southern blot using a fragment of the mouse HGF promoter that corresponds to the 5'-¯anking portion as a probe. As shown in Figure 7 , other than the major band which is the EcoRI/HindIII generated 3.5 kb HGF promoter fragment, at least ®ve bands are noted. These bands resulted from DNaseI digestion of the major fragment and correspond to the DNaseI hypersensitive sites (HSS 1 ± 5 in Figure 7 ) in the 5'-¯anking region of the HGF promoter. They are located approximately at positions 71.8, 71.5, 71.0, 70.7 and 70.3 kb from the transcription start site. It is interesting to note that some of these hypersensitive sites are located near the Sp1 sites mentioned above which are at positions 71826, 71508, 71319, 71022, 7315 and 7202 bp (Figure 6a ). We performed similar DNaseI hypersensitivity analysis on nuclei isolated from Hepa1 ± 6 cells (a mouse hepatocellular carcinoma cell line (purchased from ATCC) which does not express HGF) and did not detect signi®cant DNaseI hypersensitive sites (data not shown).
Discussion
In the present work, we have analysed an enhancer element in the mouse HGF promoter region. The regulatory binding proteins of this cis-acting element were characterized, and their functional contribution to HGF gene regulation was determined. By using transient transfection and gel mobility competition assays, the enhancer element was mapped to a region consisting of ®fteen nucleotides (7318 bp to 7303 bp) in the mouse HGF promoter region. This region has a CTCCC motif which resembles a binding site for the Sp1 transcription factor. Two major DNA-protein complexes were detected by gel mobility shift assays using an oligonucleotide probe corresponding to this region and nuclear protein extracts from ®broblast cell lines NIH3T3 and MRC-5. We showed by gel mobility supershift assays that these complexes are composed of transcription factors Sp1 and Sp3. The Sp1 region is highly conserved in human and mouse HGF promoters, and both have the same binding activities for Sp1 and Sp3 transcription factors. When the Sp1 binding site was mutated (CC to AA), the enhancing function of this region was diminished and the binding of Sp1 and Sp3 to this region were totally abrogated. Cotransfection experiments using Sp1 and Sp3 expression vectors showed that these two factors stimulate the HGF promoter in NIH3T3 cells. Four dierent members of the Sp family of transcription factors named Sp1 ± Sp4 have been identi®ed thus far. Sp1, Sp3 and Sp4 have similar structural features. Most signi®cantly, the DNA binding domains of all of these three proteins are highly conserved, and all three proteins recognize the GC box or a CACCC motif (Hagen et al., 1994; Gidoni et al., 1984) . In contrast to these factors, Sp2 seems to have a dierent DNA binding speci®city (Kingsley and Winoto, 1991) . Functional analysis of Sp3 and Sp4 in direct comparison with Sp1 revealed that Sp4, like Sp1, is a transcriptional activator, whereas Sp3 mainly functions as a repressor of Sp1-mediated transactivation (Hagen et al., 1994) . Our data indicate that Sp3 acts as an activator rather than a repressor of the HGF promoter. We showed that Sp1 and Sp3 induce the HGF gene promoter through binding to the CTCCC motif at position 7312 bp within the HGF gene promoter. The results of our DNaseI hypersensitive site analysis (Figure 7) indicates that at least ®ve hypersensitive sites are present within 2 kb of the 5'-¯anking region of the mouse HGF gene promoter. Interestingly, some of these sites colocalize with Sp1 binding sites including the major Sp1 site at position 7315 bp. This ®nding suggests that the Sp1 sites may be assessible in vivo to transcription factors such as Sp1 and Sp3 and contribute to the transcriptional activation of the HGF gene. The contribution of these HSS to the activity of the HGF gene promoter remains to be further investigated.
Although the Sp1 and Sp3 binding motif (CTCCC) in the HGF promoter has one mismatch as compared to the published CACCC consensus binding site for Sp1, and also diers from the classical GC box, it still has a very strong binding anity for Sp1 and Sp3 transcription factors. This result is consistent with the observation that the recognition sequence for the members of the Sp family of transcription factors is highly variable, and it deviates¯exibly from the consensus Sp1 binding site (Kadonaga et al., 1986; Saer et al., 1990) . Unlike Sp1, Sp2 and Sp3 which are ubiquitously expressed in various tissues and cell types, Sp4 is known to be brain-speci®c (Kingsley and Winoto, 1991; Fischer et al., 1993; Hagen et al., 1992) . Thus Sp4 may activate HGF expression in the central nervous system since the HGF gene is also expressed in this tissue (Jung et al., 1994) .
Expression of the HGF gene is restricted to the stromal cells (as epithelial cells do not express this gene) of various organs including liver, lung, spleen and kidney (Sonnenberg et al., 1993) . On the other hand, both Sp1 and Sp3 are expressed ubiquitously as mentioned (Dennig et al., 1995) . Moreover, the relative amount of the two proteins varies only modestly among dierent cell lines (Hagen et al., 1994 ). We detected a high level of Sp1 and Sp3 binding activity in the nuclear extracts from various epithelial cells such as hepatocellular carcinoma cell lines (which also do not express the HGF gene) when we used the HGF Sp1 site (7328 to 7297 bp) as a probe. Thus, the Sp1 binding site in the HGF promoter appears to be necessary but not sucient for HGF transcription and acts as a general rather than a cell-type speci®c regulator of HGF gene expression. The combinatorial action of various factors such as transcriptional factors and chromatin structure (i.e. accessibility of the Sp1 site) may dictate the cell-type speci®c expression of the HGF gene. In fact, analysis of freshly isolated nuclei from cultured Hepa1 ± 6 cells (a mouse hepatocellular carcinoma cell line which does not express the HGF gene) by DNaseI hypersensitivity assay did not reveal significant hypersensitivity indicating that the HGF promoter and its¯anking region in epithelial cells may not be readily accessible to transcription factors. In HGF expressing cells, other cis-acting elements both upstream/downstream of the Sp1 binding site in the HGF promoter may also cooperate with Sp1 to confer full promoter activity. This is consistent with the notion that synergy among multiple activators (such as Sp1) enhances preinitiation complex formation by promoting stabilized binding of TFIID to the promoter and subsequent recruitment of other basal transcription factors, whereas a single activator is unable to do so (Chi et al., 1995; Buratowski et al., 1995; Sauer et al., 1995) .
Our data showed that the 2.7 HGF-CAT construct has a stronger response to Sp1 and Sp3 cotransfection than the shorter HGF-CAT constructs (Figure 6b ). We also found ®ve minor Sp1 binding sites present in the 5'-¯anking region of the HGF promoter which have relatively lower anity (approximately 20% of that of the major Sp1 site as determined by gel shift assays) for Sp1 and Sp3 transcriptional factors. These sites may cooperate with the major Sp1 site, thus resulting in a higher induction of HGF promoter activity in response to Sp1 and Sp3 cotransfection. However, as mentioned above, we can not exclude the possibility that Sp1 and Sp3 bound to the major Sp1 site cooperate with other -HSS 5 Figure 7 Identi®cation of DNaseI hypersensitive sites in the 5'-anking region of the mouse HGF promoter. Freshly isolated nuclei from NIH3T3 ®broblasts were treated with the indicated amounts of DNaseI, then their genomic DNA was extracted, transcription factors bound to other sites in the 5'-anking region of the mouse HGF promoter, since it is known that Sp1 cooperates with several transcription factors such as p53 (Gualberto and Baldwin, 1996) , GATA-1 (Merika and Orkin, 1995), YY1 (Seto et al., 1993) , E1a (Wagner and Green, 1994) and E2F (Lin et al., 1996) . Control of HGF gene expression is complex. Our previous work showed that there is a major negative regulatory element at position 7872 bp in the 5'-anking region of the mouse HGF gene promoter. This element turned out to be an imperfect ERE that suppresses HGF gene promoter activity by binding to a nuclear orphan receptor, COUP-TF (Jiang et al., 1997) . The Estrogen receptor (ER) can compete with COUP-TF and relieve the repressive function of COUP-TF exerted on the HGF promoter through binding to the same imperfect ERE element. Additionally, we found that an element in the core HGF promoter at position 76 bp via binding to an inducible transcription factor of the C/EBP family is responsible for stimulation of the HGF gene by TPA, IL-6 and TNFa (Jiang et al., 1997) . Furthermore, other regulatory epigenetic events such as DNA methylation of the HGF promoter and nucleosome phasing at speci®c activation sites may confer higher levels of speci®city and complexity to the regulation of HGF expression in vivo.
Given the importance of stromal-epithelial interactions in normal growth and cancer, the pivotal role that HGF plays in these processes (Goldberg and Rosen, 1995) and the fact that HGF gene regulation is aberrant in neoplasms , we are now able to partially explain the molecular basis of HGF gene transcription in some stromal cells such as ®broblasts. More detailed understanding awaits the characterization of other cooperating elements and factors. Nevertheless, characterization of the Sp1 binding site in the HGF promoter and its interaction with Sp1 and Sp3, which we showed play essential roles in regulation of HGF transcription, will help us to de®ne the molecular interplay among multiple cisacting elements and trans-acting factors in the regulation of HGF transcription under various normal and pathological conditions.
Materials and methods
Plasmid construction
2.7 mouse HGF-CAT (72674 to +29 bp), 1.4 mouse HGF-CAT (71386 to +29 bp), 0.7 mouse HGF-CAT (7699 to +29 bp), 0.5 mouse HGF-CAT (7538 to +29 bp), 0.3 mouse HGF-CAT (7274 to +29 bp) and 0.1 mouse HGF-CAT (770 to +29 bp) constructs were prepared as described (Liu et al., 1994) . The 0.4 mouse HGF-CAT construct was made by double-digesting 1.4 mouse HGF-CAT with HindIII/NsiI. The 0.4 D mouse HGF-CAT construct harboring an internal deletion was generated by digesting the 0.5 mouse HGF-CAT construct with SacI and NsiI. Blunt ends were created by either Klenow polymerase or T4 DNA polymerase, and the corresponding fragments were puri®ed by gel electrophoresis and then ligated. For mutant constructs containing the mutant Sp1 binding site, a mutant oligonucleotide corresponding to the sequence from 7384 bp (NsiI site) to 7271 bp (SacI site) in the mouse HGF gene promoter was synthesized and then ligated into the 1.4 mouse HGF-CAT construct by replacing the corresponding wild type DNA fragment. The 0.7 mutant HGF-CAT and 0.4 mutant HGF-CAT constructs were made by double-digesting the 1.4 mutant mouse HGF-CAT construct with HindIII/BstXI and HindIII/NsiI respectively. Blunt ends were created by T4 DNA polymerase, and the corresponding fragments were puri®ed by gel and then ligated. The sequences of all constructs were con®rmed by DNA sequencing and restriction enzyme digestion mapping. The Sp1 (pSV-Sp1) and Sp3 (CMV-Sp3) expression vectors were gifts from Dr R Tjian and Dr G Suske, respectively.
Cell culture, DNA transfection and CAT assay
Mouse ®broblast NIH3T3 cells were cultured as described previously (Jiang et al., 1997) . For transfection, the recipient cells were cultured in six-well plates for 24 h and then transfected with various mouse HGF promoter-CAT chimeric plasmids using the DNA calcium phosphate method according to the instructions of the CellPhect transfection kit (Pharmacia LKB Biotechnology Inc.). The b-galactosidase reference plasmid pCH110 (Pharmacia) was used as an internal standard for transfection eciency. The amount of plasmid used in transfection per one well was the following: 5 mg of one chimerical CAT construct and 1 mg pCH110. After incubation of the cells with DNAcalcium phosphate buer for 16 h, the cells were washed twice with serum-free medium. Complete medium containing 10% fetal calf serum was added, and the cells were incubated for an additional 24 h before harvesting for chloramphenicol acetyltransferase (CAT) assay. Chloramphenicol acetyltransferase (CAT) activity was determined as described (Jiang et al., 1997) . Transfections were performed at least four separate times with two independent preparations of puri®ed plasmid DNA.
For cotransfection with pSV-Sp1 (Sp1 expression vector) and CMV-Sp3 (Sp3 expression vector) in NIH3T3 cells, the amount of plasmid used in transfection per one well was the following: 5 mg of one chimerical CAT construct, 1 mg pCH110 and 5 mg pSV-Sp1 and/or 5 mg CMV-Sp3 expression vectors. The total amount of DNA per each well was balanced by inclusion of empty expression vector.
Preparation of nuclear extracts
Mouse ®broblast NIH3T3 cells and human embryonic lung ®broblast MRC-5 cells were originally obtained from the American Type Culture Collection (Rockville, MD) and cultured in the conditions described previously (Liu et al., 1994; Jiang et al., 1997) . The nuclear extracts were prepared as described previously (Jiang et al., 1997) . Brie¯y, cells growing at about 90% con¯uence were washed with cold phosphate-buered saline (PBS) and scraped o with a rubber policeman. Cells were pelleted by low-speed centrifugation and then resuspended in ®ve volumes of buer A containing protease inhibitors (10 mM N-2-hydroxyethylpiperazine-N'-2-ethane-sulfonic acid [HEPES; pH 7.9], 1.5 mM MgCl 2 , 10 mM KCl, 0.2 mM PMSF, 0.15 mM spermidine, 0.5 mM spermine, 0.5% Nonidet P-40 and 0.5 mM dithiothreitol, plus 1 mg each of leupeptin and chymostatin per ml). The cells were then subjected to hypotonic shock for 10 min on ice. An equal volume of buer A containing 0.6% Nonidet P-40 was added with gentle mixing to lyse the cells. Immediately after lysis, the solution was transferred to a glass Dounce homogenizer and homogenized with ten up-and-down strokes using a type B pestle. The nuclei were collected by centrifuging 15 min at 3300 g and resuspended in the same volume of buer B as buer A. The contents of buer B were the same as buer A except no Nonidet P-40 was added. After the nuclei were recovered by centrifugation, a certain volume of buer C (20 mM HEPES, [pH 7.9], 10% Glycerol, 1.5 mM MgCl 2 , 10 mM KCl, 0.2 mM PMSF, 0.5 mM dithiothreitol, plus 1 mg each of leupeptin and chymostatin per ml) was added to resuspend the nuclei. Nuclear protein was extracted in buer D (the same as buer C, but substituting 10 mM KCl for 1.6 M KCl) for 1 h on ice as previously described (Jiang et al., 1997) . The extracted nuclei were centrifuged for 45 min at 50 000 g at 48C, and the supernatant was then collected and dialyzed against 60 mM KCl-TGM buer, using a mini-dialysis system (Gibco/BRL, Gaithersburg, MD). Insoluble materials were removed by centrifugation, and small aliquots of protein extract were quickly frozen and stored at 7808C after the protein concentration had been determined (protein assay; Bio-Rad, Richmond, California).
Oligonucleotides and antibodies
The following oligonucleotides and antibodies were obtained from Santa Cruz Biotechnology, Inc. and were used in gel mobility shift assays: Sp1, ATTCGAT-CGGGGCGGGGCGAGC; Sp1 mutant: ATTCGATCG-GTTCGGGGCGAG; Anti-Sp1, anti-Sp3, anti-AP2 and anti-ER antibodies. The following synthesized oligonucleotides containing the minor Sp1 sites in the 5'-¯anking region of the mouse HGF gene promoter were used as competitors in gel mobility shift assays for comparison of their Sp1 and Sp3 binding anities with the major Sp1 site: 71833 to 71813: 5'-GGAAAATGGGCGGGAACCTT-3'; 71513 to 71493: 5'-CTTCTCCCTCCCCTTCATTT-3'; 71323 to 71303: 5'-GAAAGGCCACCCTATTACTG-3'; 71028 to 71008: 5'-CTGCTTCCTCCCTCCCTGAA-3'; 7168 to 7148: 5'-TTGTTGGGGGGGGGGGGGGT-3'.
Gel retardation assays
A DNA fragment corresponding to position 7384 to 7274 bp of the 5'-¯anking region of the mouse HGF gene was isolated from chimeric plasmid 0.5 mHGF-CAT. Following restriction digestion of the 0.5 mHGF-CAT construct with NsiI and SacI, the 111 bp fragment was puri®ed and labeled with [g-32 P]dATP (6000 Ci mmol; Amersham) by T4 kinase (Gibco/BRL). The double stranded oligonucleotides used in gel shift assays were labeled with [a-32 P]dCTP by end labeling with Klenow fragment of DNA polymerase. The labeled oligonucleotide probes were then gel puri®ed and used in gel mobility shift assays as described previously (Jiang et al., 1997) . One microgram of poly(dI-dC) (Pharmacia, Piscataway, NJ) was used as the nonspeci®c competitor in 10 ml of reaction mixture. When antibodies (1 ml or 2 ml) for supershift assays were used, they were incubated with nuclear extracts for 30 min at room temperature before performing DNA binding assays. The binding reactions were carried out at room temperature for 20 min before loading on 5% nondenaturing polyacrylamide (19 : 1; acrylamide/bisacrylamide) gels. The amount of nuclear protein extracts used in each reaction was 4 mg, and that of the labeled probe was between 0.2 and 0.4 ng. For competition experiments, a 100-fold molar excess of unlabeled DNA fragments or oligonucleotides, unless indicated otherwise in experiments, was included in the reaction mixture. Gels were run in 0.56TBE buer (0.045 M Tris-borate, 0.001 M EDTA) at a constant voltage of 190 V, dried, and autoradiographed with intensifying screens.
DNaseI hypersensitivity assays
Freshly isolated nuclei from cultured NIH3T3 ®broblasts were subjected to limited DNaseI digestion (1 min on ice with the indicated units of DNaseI) as described by Burkowitz et al. (1996) . Genomic DNA was then extracted from nuclei by phenol/chloroform and subjected to restriction enzyme digestion using EcoRI/HindIII which release a 3.5 kb fragment of the mouse HGF promoter consisting of 72.8 kb of the 5'-¯anking, the ®rst exon (*90 bp) and part of the ®rst intron (*600 bp) (Liu et al., 1994) . Equivalent amounts of the digested DNA were then analysed by Southern blot using a fragment of DNA (HindIII/BglII) that corresponded to the 5'-¯anking region of the mouse HGF promoter as a probe. Molecular size standards (l phage and f174 DNAs (Gibco BRL)) were used to estimate the size of the DNaseI hypersensitive fragments.
Abbreviations HGF, hepatocyte growth factor; CAT, chloramphenicol acetyltransferase; kb, kilobase pair(s); bp, base pair(s); t, top complex; b, bottom complex; Ab, antibody; HSS, DNaseI hypersensitive site.
